PMV Pharmaceuticals (PMVP) Return on Capital Employed (2020 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Return on Capital Employed came in at 85.4% in Q1 2026, down 3353.0% YoY from 2.63% in Q1 2025, and down 12.72% on a QoQ basis from 75.76% in Q4 2025.
PMV Pharmaceuticals (PMVP) Return on Capital Employed (2020 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 7 years of Return on Capital Employed data on file, last reported at 85.4% in Q1 2026.
- Quarterly Return on Capital Employed fell 3353.0% year-over-year to 85.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 85.4% (down 3353.0% YoY) and the FY2025 annual result came in at 60.49%, down 1928.0% from the prior year.
- Return on Capital Employed fell to 85.4% in Q1 2026, from 75.76% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.94% in Q1 2022 to a low of 85.4% in Q1 2026.
- A 5-year average of 42.69% and a median of 34.2% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 65 bps — and 2025, when it tumbled 3381 bps.
- Tracing PMVP's Return on Capital Employed over 5 years: stood at 28.87% in 2022, then declined by 14 bps to 33.04% in 2023, then slumped by 34 bps to 44.27% in 2024, then tumbled by 71 bps to 75.76% in 2025, then decreased by 13 bps to 85.4% in 2026.
- The last three Return on Capital Employed figures came in at 85.4% (Q1 2026), 75.76% (Q4 2025), and 70.31% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | PMV Pharmaceuticals | 71.27 Mn | -8.16 Mn | - | -101.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.40% |
| Dec 31, 2025 | -75.76% |
| Sep 30, 2025 | -70.31% |
| Jun 30, 2025 | -60.95% |
| Mar 31, 2025 | -51.87% |
| Dec 31, 2024 | -44.27% |
| Sep 30, 2024 | -36.50% |
| Jun 30, 2024 | -34.06% |
| Mar 31, 2024 | -33.07% |
| Dec 31, 2023 | -33.04% |
| Sep 30, 2023 | -34.20% |
| Jun 30, 2023 | -34.71% |
| Mar 31, 2023 | -31.76% |
| Dec 31, 2022 | -28.87% |
| Sep 30, 2022 | -26.45% |
| Jun 30, 2022 | -23.64% |
| Mar 31, 2022 | -20.94% |
| Dec 31, 2021 | -17.90% |
| Sep 30, 2021 | -14.74% |
| Jun 30, 2021 | -12.64% |